Total Beta-Adrenoceptor Knockout Slows Conduction and Reduces Inducible Arrhythmias in the Mouse Heart

Introduction Beta-adrenoceptors (β-AR) play an important role in the neurohumoral regulation of cardiac function. Three β-AR subtypes (β1, β2, β3) have been described so far. Total deficiency of these adrenoceptors (TKO) results in cardiac hypotrophy and negative inotropy. TKO represents a unique mouse model mimicking total unselective medical β-blocker therapy in men. Electrophysiological characteristics of TKO have not yet been investigated in an animal model. Methods In vivo electrophysiological studies using right heart catheterisation were performed in 10 TKO mice and 10 129SV wild type control mice (WT) at the age of 15 weeks. Standard surface ECG, intracardiac and electrophysiological parameters, and arrhythmia inducibility were analyzed. Results The surface ECG of TKO mice revealed a reduced heart rate (359.2±20.9 bpm vs. 461.1±33.3 bpm; p<0.001), prolonged P wave (17.5±3.0 ms vs. 15.1±1.2 ms; p = 0.019) and PQ time (40.8±2.4 ms vs. 37.3±3.0 ms; p = 0.013) compared to WT. Intracardiac ECG showed a significantly prolonged infra-Hisian conductance (HV-interval: 12.9±1.4 ms vs. 6.8±1.0 ms; p<0.001). Functional testing showed prolonged atrial and ventricular refractory periods in TKO (40.5±15.5 ms vs. 21.3±5.8 ms; p = 0.004; and 41.0±9.7 ms vs. 28.3±6.6 ms; p = 0.004, respectively). In TKO both the probability of induction of atrial fibrillation (12% vs. 24%; p<0.001) and of ventricular tachycardias (0% vs. 26%; p<0.001) were significantly reduced. Conclusion TKO results in significant prolongations of cardiac conduction times and refractory periods. This was accompanied by a highly significant reduction of atrial and ventricular arrhythmias. Our finding confirms the importance of β-AR in arrhythmogenesis and the potential role of unspecific beta-receptor-blockade as therapeutic target.

[1]  D. Kass,et al.  Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase. , 2012, Journal of the American College of Cardiology.

[2]  J. Baker,et al.  The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptors , 2010, British journal of pharmacology.

[3]  L. Barouch,et al.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system. , 2010, Journal of molecular and cellular cardiology.

[4]  D. Kass,et al.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor. , 2009, Journal of molecular and cellular cardiology.

[5]  Yuan-yuan Wang,et al.  Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation. , 2009, Cardiovascular research.

[6]  J. Trochu,et al.  Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart. , 2009, Journal of the American College of Cardiology.

[7]  R. Bache,et al.  Regulation of coronary blood flow during exercise. , 2008, Physiological reviews.

[8]  D. Bers,et al.  Arrhythmogenic Effects of &bgr;2-Adrenergic Stimulation in the Failing Heart Are Attributable to Enhanced Sarcoplasmic Reticulum Ca Load , 2008, Circulation research.

[9]  D. Ben-sira,et al.  The Effect of Long‐Term β‐Adrenergic Receptor Blockade on the Oxygen Delivery and Extraction Relationship in Patients With Coronary Artery Disease , 2008, Journal of cardiopulmonary rehabilitation and prevention.

[10]  Weimin Li,et al.  Chronic blocking of β3-adrenoceptor ameliorates cardiac function in rat model of heart failure , 2007 .

[11]  J. Balligand,et al.  Sepsis is associated with an upregulation of functional β3 adrenoceptors in the myocardium , 2007, European journal of heart failure.

[12]  B. Fleischmann,et al.  Enhanced heterogeneity of myocardial conduction and severe cardiac electrical instability in annexin A7-deficient mice. , 2007, Cardiovascular research.

[13]  W. Gibler,et al.  Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. , 2007, The American journal of medicine.

[14]  Le-Xin Wang,et al.  Effect of β-Blockers on β3-Adrenoceptor Expression in Chronic Heart Failure , 2007, Cardiovascular Drugs and Therapy.

[15]  Matthew J. Killeen,et al.  The contribution of refractoriness to arrhythmic substrate in hypokalemic Langendorff-perfused murine hearts , 2007, Pflügers Archiv - European Journal of Physiology.

[16]  R. Schwinger,et al.  Beta3-adrenergic eNOS stimulation in left ventricular murine myocardium. , 2006, Canadian journal of physiology and pharmacology.

[17]  M. Palkovits,et al.  Distribution of mRNA and binding sites of adrenoceptors and muscarinic receptors in the rat heart. , 2006, Life sciences.

[18]  Alexander Ghanem,et al.  Connexin30.2 containing gap junction channels decelerate impulse propagation through the atrioventricular node. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Michael Kohlhaas,et al.  Increased Sarcoplasmic Reticulum Calcium Leak but Unaltered Contractility by Acute CaMKII Overexpression in Isolated Rabbit Cardiac Myocytes , 2006, Circulation research.

[20]  G. Berry,et al.  Differential cardioprotective/cardiotoxic effects mediated by beta-adrenergic receptor subtypes. , 2005, American journal of physiology. Heart and circulatory physiology.

[21]  Jillian G. Baker,et al.  The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors , 2005 .

[22]  B. Fleischmann,et al.  Mechanisms of β3‐adrenoceptor‐induced eNOS activation in right atrial and left ventricular human myocardium , 2004, British journal of pharmacology.

[23]  W. Little,et al.  Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. , 2004, American journal of physiology. Heart and circulatory physiology.

[24]  B. Kobilka,et al.  Protecting the myocardium: A role for the &bgr;2 adrenergic receptor in the heart , 2004, Critical care medicine.

[25]  J. Norrie,et al.  Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. , 2003, Cardiovascular research.

[26]  B. Kobilka,et al.  Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. , 2003, The Journal of clinical investigation.

[27]  G. Wallukat,et al.  The β-Adrenergic Receptors , 2002, Herz.

[28]  A. Russell,et al.  β1/β2/β3‐adrenoceptor knockout mice are obese and cold‐sensitive but have normal lipolytic responses to fasting , 2002 .

[29]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[30]  B. Lüderitz,et al.  Induction of atrial fibrillation in mice by rapid transesophageal atrial pacing , 2002, Basic Research in Cardiology.

[31]  D. Bernstein.  Cardiovascular and Metabolic Alterations in Mice Lacking β1- and β2-Adrenergic Receptors , 2002 .

[32]  J. Balligand,et al.  Upregulation of &bgr;3-Adrenoceptors and Altered Contractile Response to Inotropic Amines in Human Failing Myocardium , 2001, Circulation.

[33]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[34]  B. Kobilka,et al.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Raynolds,et al.  Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. , 2000, Journal of molecular and cellular cardiology.

[36]  G. Salama,et al.  Enhanced dispersion of repolarization and refractoriness in transgenic mouse hearts promotes reentrant ventricular tachycardia. , 2000, Circulation research.

[37]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[38]  K. Desai,et al.  Targeted Disruption of the β2 Adrenergic Receptor Gene* , 1999, The Journal of Biological Chemistry.

[39]  D. Bernstein,et al.  Cardiovascular and Metabolic Alterations in Mice Lacking Both β1- and β2-Adrenergic Receptors* , 1999, The Journal of Biological Chemistry.

[40]  E. Lakatta,et al.  Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. , 1999, Circulation research.

[41]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[42]  G. Mitchell,et al.  Measurement of heart rate and Q-T interval in the conscious mouse. , 1998, American journal of physiology. Heart and circulatory physiology.

[43]  Robert J. Lefkowitz,et al.  Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A , 1997, Nature.

[44]  G. Barsh,et al.  Targeted disruption of the mouse beta1-adrenergic receptor gene: developmental and cardiovascular effects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Richard V. Lewis,et al.  Adverse Reactions with β-Adrenoceptor Blocking Drugs , 1993 .

[46]  O. Brodde.  Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. , 1991, Pharmacological reviews.

[47]  A. Strosberg,et al.  Molecular characterization of the human beta 3-adrenergic receptor. , 1989, Science.

[48]  M. Caron,et al.  Cloning of the cDNA for the human beta 1-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Brian K. Kobilka,et al.  Cloning of the gene and cDNA for mammalian β-adrenergic receptor and homology with rhodopsin , 1986, Nature.

[50]  A. Camm,et al.  Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. , 1986, The American journal of cardiology.

[51]  S. Olsson,et al.  Induction of delayed repolarization during chronic beta-receptor blockade. , 1985, European heart journal.

[52]  A. K. Dawson,et al.  Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. , 1983, Journal of the American College of Cardiology.

[53]  S. Swiryn,et al.  Significance of the HV interval in 517 patients with chronic bifascicular block. , 1981 .

[54]  A. Raine,et al.  Adaptation to prolonged beta-blockade of rabbit atrial, purkinje, and ventricular potentials, and of papillary muscle contraction. Time-course of development of and recovery from adaptation. , 1981, Circulation research.

[55]  S. Swiryn,et al.  Natural History of Chronic Second‐degree Atrioventricular Nodal Block , 1981, Circulation.

[56]  S. Swiryn,et al.  Significance of the HV Interval in 517 Patients with Chronic Bifascicular Block , 1980, Circulation.

[57]  J. Haft.  Cardiovascular injury induced by sympathetic catecholamines. , 1974, Progress in cardiovascular diseases.

[58]  E. Donoso,et al.  NONSURGICAL ACQUIRED HEART BLOCK * , 1963, Annals of the New York Academy of Sciences.

[59]  M. Campbell.  COMPLETE HEART BLOCK , 1944, British heart journal.

[60]  F. Marchlinski,et al.  Mechanisms of cardiac arrhythmias. , 2012, Revista espanola de cardiologia.

[61]  D. Bernstein,et al.  THE ROLE OF β-ADRENERGIC RECEPTORS IN HEART FAILURE: DIFFERENTIAL REGULATION OF CARDIOTOXICITY AND CARDIOPROTECTION. , 2011, Progress in pediatric cardiology.

[62]  R. Schwinger,et al.  Total beta-adrenoceptor deficiency results in cardiac hypotrophy and negative inotropy. , 2010, Physiological research.

[63]  Weimin Li,et al.  Chronic blocking of beta 3-adrenoceptor ameliorates cardiac function in rat model of heart failure. , 2007, Chinese medical journal.

[64]  D. Bernstein,et al.  Effect of targeted deletions of beta1- and beta2-adrenergic-receptor subtypes on heart rate variability. , 2006, American journal of physiology. Heart and circulatory physiology.

[65]  D. Bernstein,et al.  Effect of targeted deletions of β1- and β2-adrenergic-receptor subtypes on heart rate variability , 2006 .

[66]  J. Baker.  The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. , 2005, British journal of pharmacology.

[67]  A. Russell,et al.  Beta(1)/beta(2)/beta(3)-adrenoceptor knockout mice are obese and cold-sensitive but have normal lipolytic responses to fasting. , 2002, FEBS letters.

[68]  D. Bernstein.  Cardiovascular and metabolic alterations in mice lacking beta1- and beta2-adrenergic receptors. , 2002, Trends in cardiovascular medicine.

[69]  D. Sawyer,et al.  Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. , 1999, Circulation.

[70]  R. Lewis,et al.  Adverse reactions with beta-adrenoceptor blocking drugs. An update. , 1993, Drug safety.

[71]  D. Atlas,et al.  The Metabotropic Glutamate Receptors , 1994, The Receptors.

[72]  B. Johansson.  Complete heart block. A clinical, hemodynamic and pharmacological study in patients with and without an artificial pacemaker. , 1966, Acta medica Scandinavica. Supplementum.

[73]  Johansson Bw.  Complete heart block. A clinical, hemodynamic and pharmacological study in patients with and without an artificial pacemaker. , 1966 .